生长激素释放激素 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-23. Numbers and descriptions here follow the published literature rather than marketing material.
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | N-terminal trans-3-hexenoyl group |
| Approximate mass | About 5.1 kDa | Derived from the peptide sequence |
| Primary target | Pituitary GHRH receptor | Somatotroph cells of the anterior pituitary |
| Downstream marker | IGF-1 | Measured indirectly in circulation |
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
==== Anti-scatter grid ==== An anti-scatter grid is a device in X-ray technology that is placed in front of the image receiver (screen, detector, or film) and reduces the incidence of diffuse radiation on it. The first diffusion radiation grid was developed in 1913 by Gustav Peter Bucky (1880-1963). The US radiologist Hollis Elmer Potter (1880-1964) improved it in 1917 by adding a moving device. The radiation dose must be increased when using scattered radiation grids. For this reason, the use of scattered radiation equipment should not be used on children. In digital radiography, a grid may be omitted under certain conditions to reduce radiation exposure to the patient.
== Independent evaluation of the software == CASMI (Critical Assessment of Small Molecule Identification) is an open contest on the identification of small molecules from mass spectrometry data, and was launched in 2012 by Emma Schymanski and Steffen Neumann. In CASMI 2016, CSI:FingerID and a derivative of CSI:FingerID, in which the Böcker Group was also involved, won first and second place in the category "Best Automatic Structural Identification - In Silico Fragmentation Only". Also, CSI:FingerID had the best result for ranking the correct molecule structure at position one (70 out of 127, positive mode). In CASMI 2017, SIRIUS plus CSI:FingerID won in 3 of 4 categories: "Best Structure Identification on Natural Products", "Best Automatic Structural Identification - In Silico Fragmentation Only", "Best Automatic Candidate Ranking". In CASMI 2022, six out of 16 contestants used SIRIUS in their workflow to identify the best molecular structure candidates. SIRIUS won in the categories "Correct elemental formulas", "Correct compound structure classes" and "Correct 2D chemical structures". CASMI 2022 included compounds that were not even contained in PubChem.
== Interactions == Being metabolized only to a small extent, the substance has a low potential for interactions. In studies, inhibitors of the liver enzymes CYP3A4, CYP2C19, and CYP2C9, as well as the CYP3A4 inducer rifampicin, had no relevant influence on baricitinib concentrations in the bloodstream. While baricitinib blocks a number of transporter proteins in vitro, clinically relevant interactions via this mechanism are considered very unlikely, except perhaps for the cation transporter SLC22A1 (OCT1). An additive effect with other immunosuppressants cannot be excluded.
Javed Butler is an American cardiologist and academic, recognized for his contributions to cardiovascular medicine, particularly in heart failure research. He serves as the Maxwell A. and Gayle H. Clampitt Endowed Chair, president, and chief research executive at Baylor Scott & White Research Institute, and senior vice president at Baylor Scott & White Health in Dallas, Texas. He is a fellow of Heart Failure Society of America, European Society of Cardiology, American College of Cardiology, and American Heart Association.
Sources: en.wikipedia.org
=== The Ait Soussan organisation === The Ait Soussan organisation is a criminal organisation led by Houssine Ait Soussan. He is a major drug trafficker who also used to own the Dutch football-club ZVV 't Knooppunt. Houssine Ait Soussan is notably a prominent figure within the Moroccan mafia in the Netherlands and Belgium, and he was also allied with the Bouyakhrichan organisation. The Ait Soussan organisation is responsible for distributing tons of cocaine across all of Western Europe. Houssine Ait Soussan is also considered to be one of the original participating figures within the Mocro-War, which was sparked after a missing shipment of cocaine in the port of Antwerp. As a result of this, Houssine Ait Soussan is believed to be behind the kidnapping of Abdelkader "the Jew" Bouker, a major Belgian-Moroccan drug trafficker who worked closely together with the Israeli mafia, and went missing in 2016. He was also believed to be behind the kidnapping of Younes El Ballouti, the younger brother of Othman El Ballouti, who is considered to be one of the biggest drug lords in Belgium. Houssine Ait Soussan allegedly kidnapped him as revenge, because Colombian cartels preferred to work with the El Ballouti clan instead of his organisation. Houssine Ait Soussan was for many years wanted by the Dutch and Belgian authorities for his involvement in numerous of assassinations and kidnappings, which mostly took place in Antwerp and Brussels. He orchestrated his kidnappings and assassinations from Central America, to stay off the radar from the European police.
== Examples == In the last 40 years, there has been a significant amount of research on metal binding peptides and their characteristics, structures, and chemical reactivities. Vincent L. Pecoraro and his group investigate the interaction of peptides with heavy metals in the body; Katherine Franz leads a group studying Cu-binding peptides; Angela Lombardi and her unit focus on the development of artificial metalloenzymes and similar peptide systems, and the group of Peter Faller focuses on redox reactivity of Cu-peptides.
=== Historical misuse === Opiate misuse has been recorded at least since 300 BC. Greek mythology describes Nepenthe ("free from sorrow") and its use by the hero of the Odyssey. Opioids have been used in the Near East for centuries. They were purified and isolated in the early 19th century. In the early 2000s, buprenorphine was one of the first opioid dependence drugs approved in the U.S. to combat opioid abuse, after decades of research led to the development of drugs to fight opioid use disorder.
MVA-BN (brand names: Imvanex, Imvamune, and Jynneos) is a modified vaccinia Ankara (MVA) vaccine manufactured by Bavarian Nordic by growing MVA in cell culture. Unlike replicating vaccines, MVA-BN is administered by injection via the subcutaneous route and does not result in a vaccine "take." A "take" or "major cutaneous reaction" is a pustular lesion or an area of definite induration or congestion surrounding a central lesion, which can be a scab or an ulcer. MVA-BN can also be administered intradermally to increase the number of available doses. It is safer for immunocompromised patients and those who are at risk from a vaccinia infection. MVA-BN has been approved in the European Union, Canada, and the United States. Clinical trials have found that MVA-BN is safer and just as immunogenic as ACAM2000. This vaccine has also been approved for use against mpox. It received WHO prequalification against smallpox and Mpox in September 2024.
In 1946, Commodore Alfred Victor Knight of the Royal Australian Navy was awarded the commendation for honorary services. The citation described him as a 'forceful leader' who, by his 'splendid co-operation in the conduct of a vital training programme, aggressive determination and untiring energies ... contributed materially to combined large-scale operations'. On 3 September 1946, Vice Admiral Henry George Harry DeWolf of the Royal Canadian Navy was awarded the legion of Merit officer level for honorary services. The citation description "For exceptionally meritorious conduct in the performance of outstanding service while serving as Chief Staff Officer to Rear-Admiral G.C. Jones, RCN. He frequently conferred with Commander Task Force Twenty-four and his staff in connection with planning and the operational control of the surface forces under Commander Task Force Twenty-four. His excellent professional grasp of strategic and tactical situations, together with his intelligent and co-operative attitude, contributed materially to the success of operations conducted by Commander Task force Twenty-four." In 1947, Colonel Valentine Patrick Terrel Vivian head of counter-espionage, Section V, and Vice-Chief of the S.I.S. or MI6.
Sources: en.wikipedia.org
It mirrors the 44-residue form of human growth hormone-releasing hormone. A hexenoyl group on the N-terminal tyrosine distinguishes it from the unmodified hormone. The change is intended to improve resistance to enzymatic breakdown.
The N-terminal modification reduces cleavage by circulating peptidases, so the peptide persists longer than native GHRH. That persistence is the main rationale for the synthetic design. Comparative half-life values in humans are reported in regulatory review documents rather than in general reference literature.
Reductions in visceral adipose tissue have been measured in controlled studies of defined populations. Whether the effect generalizes to other groups and persists after treatment stops is less clear. Longer-term outcome data remain limited.
特沙莫瑞林是国际非专利名称，指一种经过 N 端修饰的生长激素释放激素类似物。它被归类为合成肽，序列与 GHRH(1-44) 密切相关。该名称不指代任何特定品牌或剂型。